<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82535">
  <stage>Registered</stage>
  <submitdate>15/01/2008</submitdate>
  <approvaldate>18/01/2008</approvaldate>
  <actrnumber>ACTRN12608000030370</actrnumber>
  <trial_identification>
    <studytitle>Isosorbide dinitrate and hydralazine in symptomatic systolic heart failure.</studytitle>
    <scientifictitle>Effect of Isosorbide dinitrate(ISDN) and hydralazine(HYD) on left heart filling pressures in symptomatic systolic heart failure.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is a prospective haemodynamic based study in patients with CHF and pulmonary hypertension and/or elevated estimated left atrial pressure who are already on stable and optimsed doses of traditional heart failure medications.  This will be a single center study, with enrolment expected to occur over 6 months.   Following infromed consent, there will be an initial screening phase, with the performance of a right heart study to document baseline haemodynamic data. All patients will be commenced on combination oral ISDN and HYD.  Titration of the study medications will occur over the next 2-6 weeks beginning with 60mg and 37.5mg ISDN and HYD respectively, then aiming to reach ISDN dose 120mg and HYD dose 225mg daily respectively.  A treatment phase will follow with regular review of the patients in clinic for progress and side effects of medications. At the end of the study period( 4 weeks), a repeat right heart study will be conducted to assess cardiac pressures.</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine if the use of isosorbide dinitrate(ISDN) and hydrallazine(HYD) can reduce pulmonary artery pressure(PAP) and left atrial pressure in patients with symptomatic systolic heart failure who have evidence of pulmonary hypertension(PH) and/or elevated estimated left atrial pressure as measured on right heart study.</outcome>
      <timepoint>4 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of functional/haemodynamic improvements with treatment as assessed by Transthoracic Thoracic Echocardiography criteria</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of functional/haemodynamic improvements with treatment as assessed by change in BNP( B type natriuretic peptide) levels</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of functional/haemodynamic improvements with treatment as assessed by change in Kansas city questionaire score.</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Assessment of functional/haemodynamic improvements with treatment as assessed by 6 minute walk distance</outcome>
      <timepoint>4 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>·&gt;18 year old 
·Non African background
·Heart failure as defined by Left ventricular ejection fraction ( measured on TTE)&lt; 45%New York Heart Association(NYHA) functional class II-III for at least 3 months
·Pulmonary hypertension secondary to systolic heart failure ( Right Ventricular systolic pressure (RVSP) &gt; 45mmHg on TTE)  
·On optimized and stable doses of traditional neurohormonal heart failure medications, Ace inhibitor(ACEI), Beta blockers and spironolactone for at least one month
·Systolic blood pressure &gt; 90mmHg</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>·Recent diagnosis( &lt; 3 months) Acute myodcardial infarction(AMI), Congestive cardiac failure(CCF), percutaneous coronary intervention(PCI) or cardiac surgery.
·Pregnancy 
·Significant aortic or mitral stenosis
·Concurrent illnesses likely to shorten life.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence>N/A</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>2/02/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3050</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Royal Melbourne Hospital</primarysponsorname>
    <primarysponsoraddress>Grattan Street, Parkville. 3050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>The Royal Melbourne Hospital</fundingname>
      <fundingaddress>Grattan Street, Parkville. 3050</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Isosorbide dinitrate and hydralazine have been shown in previous trials to be beneficial in heart failure patients.  Previous haemodynamic based studies have been conducted with older forms of treatment of heart failure, and larger clinical studies have been largely focused on African Americans. 
The purpose of the study is to evaluate the effect of Isosorbide dinitrate and hydralazine on Pulmonary  and left heart pressures in patients with symptomatic heart failure with documented pulmonary hypertension on comtemporary treatment.
indirect assessemt of improvement will be evaluated with functional scores, and exercise distance.
Patients meeting the study (inclusion  and exclusion) criteria will be recruited via the cardiomyopathy service (outpatient)and inpatient ward at the Royal Melbourne Hopsital. Informed consent will be obtained.  Screening phase of the study will include baseline investigations and the right heart study. Stabilisation phase takes place in next 2-4 weeks till stable doses of study medication achieved.  Treatment phase will commence and parameters reassessed at end of study period.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>The Royal Melbourne Hospital 
Grattan Street, Parkville. 3050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>21/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Melbourne Health Human Research Ethics Committee</ethicname>
      <ethicaddress>The Royal Melbourne Hospital 
Grattan Street, Parkville. 3050</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>21/01/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anuradha Aggarwal</name>
      <address>Department of Cardiology
The Royal Melbourne Hospital
Grattan Street, Parkville 3050</address>
      <phone>(03)93427133</phone>
      <fax />
      <email>Anuradha.Aggarwal@mh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ken Lu</name>
      <address>Department of Cardiology
The Royal Melbourne Hospital
Grattan Street, Parkville 3050</address>
      <phone>(03)93427000</phone>
      <fax />
      <email>Ken.Lu@mh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ken Lu</name>
      <address>Department of Cardiology
The Royal Melbourne Hospital
Grattan Street, Parkville 3050</address>
      <phone>(03)93427000</phone>
      <fax />
      <email />
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>